Table of Contents
International Journal of Molecular Imaging
Volume 2012 (2012), Article ID 175803, 6 pages
http://dx.doi.org/10.1155/2012/175803
Review Article

The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Evaluating the Response to Treatment in Patients with Multiple Myeloma

1Department of Bioimaging and Radiological Sciences, Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Largo Gemelli 8, 00168 Rome, Italy
2Institute of Biochemistry and Clinical Biochemistry, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
3School of Biotechnology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

Received 3 June 2012; Accepted 3 July 2012

Academic Editor: Hongming Zhuang

Copyright © 2012 Carmelo Caldarella et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and Aim. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is well recognized as a powerful diagnostic tool in the initial staging of patients with multiple myeloma (MM). The aim of this paper is to perform a systematic review about the usefulness of FDG-PET or PET/CT in evaluating the response to treatment in patients with MM. Methods. The scientific literature about the role of FDG-PET or PET/CT in evaluating the response to treatment in patients affected by MM was systematically reviewed. Results. Ten studies about the role of FDG-PET or PET/CT in evaluating treatment response in MM were retrieved and discussed. Conclusions. FDG-PET or PET/CT seems to be helpful in assessing the response to treatment in patients with MM and in the evaluation of possible sites of recurrent or progressive disease.